ANRIL has been shown to have a major role in promoting transcriptional repressors involved in downregulation of the CDKN2A/B genes resulting in genetic susceptibility to various cancers (Congrains et al., 2013[5]; Yap et al., 2010[33]; Popov and Gil, 2010[18]). The gene discussed is CDKN2B-AS1; the disease is cancer.